Eragidomide

DB19242InvestigationalSmall molecule

Eragidomide is under investigation in clinical trial NCT04297124 (A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects).

Mechanism: Pharmacologically active on Eukaryotic peptide chain release factor GTP-binding subunit ERF3A and Protein cereblon
Curator reviewed
Formula / weight: C₂₂H₁₈ClF₂N₃O₄ · 461.85 g/mol (avg)
Also known as: 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1h-isoindol-5-yl)methyl)-2,2-difluoroacetamide
Code names: CC-90009

Resolves to

Compound

UNIIR76M2Z6366CAS1860875-51-9ChEMBLCHEMBL4742712

Structure

InChIKeyPWBHUSLMHZLGRN-UHFFFAOYSA-NSMILESFC(F)(C(=O)NCC1=CC=C2C(=O)N(CC2=C1)C1CCC(=O)NC1=O)C1=CC=C(Cl)C=C1

Targets

P15170GSPT1Q96SW2CRBN

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Eragidomide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account